AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|AAPL324.96-0.17 (-0.05%) ▼|ABBV261.72+1.73 (+0.67%) ▲|ABT110.47+1.54 (+1.41%) ▲|ACN187.68-0.41 (-0.22%) ▼|ADBE279.79-6.29 (-2.20%) ▼|AMAT438.46-3.39 (-0.77%) ▼|AMD457.06-2.55 (-0.55%) ▼|AMGN442.84+4.72 (+1.08%) ▲|AMT172.92-3.10 (-1.76%) ▼|AMZN254.98+0.06 (+0.02%) ▲|AVGO367.24-2.44 (-0.66%) ▼|AXP329.98+5.79 (+1.79%) ▲|BA208.87+3.21 (+1.56%) ▲|BAC62.60+0.61 (+0.98%) ▲|BKNG199.60+3.91 (+2.00%) ▲|BLK1,107.08-21.02 (-1.86%) ▼|BMY67.66+0.74 (+1.11%) ▲|BNY162.04+1.53 (+0.95%) ▲|BRK-B505.24+2.91 (+0.58%) ▲|C134.34+1.80 (+1.36%) ▲|CAT792.28+13.12 (+1.68%) ▲|CL90.10+0.47 (+0.52%) ▲|CMCSA26.81+0.51 (+1.94%) ▲|COF216.60+5.26 (+2.49%) ▲|COP137.20+1.01 (+0.74%) ▲|COST928.48-11.48 (-1.22%) ▼|CRM256.93-1.18 (-0.46%) ▼|CSCO109.46-0.29 (-0.26%) ▼|CVS97.23-0.37 (-0.38%) ▼|CVX211.78+0.73 (+0.35%) ▲|DE698.37+22.29 (+3.30%) ▲|DHR209.91+2.98 (+1.44%) ▲|DIS107.98+1.76 (+1.66%) ▲|DUK120.56+0.17 (+0.14%) ▲|EMR148.98+1.35 (+0.91%) ▲|FDX316.54-8.34 (-2.57%) ▼|GD364.07-5.34 (-1.45%) ▼|GE329.50-1.59 (-0.48%) ▼|GEV921.94+23.41 (+2.61%) ▲|GILD149.61-0.31 (-0.21%) ▼|GM84.87-0.76 (-0.89%) ▼|GOOG333.78+1.75 (+0.53%) ▲|GOOGL337.12+2.10 (+0.63%) ▲|GS1,004.42+1.86 (+0.19%) ▲|HD318.51-1.26 (-0.39%) ▼|HON206.07-3.91 (-1.86%) ▼|IBM231.70+0.30 (+0.13%) ▲|INTC90.05+1.08 (+1.21%) ▲|INTU342.94-1.99 (-0.58%) ▼|ISRG371.88+2.63 (+0.71%) ▲|JNJ275.21+4.02 (+1.48%) ▲|JPM356.22+1.27 (+0.36%) ▲|KO88.24+0.24 (+0.27%) ▲|LIN487.45+0.69 (+0.14%) ▲|LLY1,160.08+0.08 (+0.01%) ▲|LMT531.55-12.95 (-2.38%) ▼|LOW199.84-0.21 (-0.11%) ▼|LRCX288.32-1.88 (-0.65%) ▼|MA588.14+7.04 (+1.21%) ▲|MCD260.95-0.16 (-0.06%) ▼|MDLZ62.45+0.84 (+1.36%) ▲|MDT92.18+0.14 (+0.15%) ▲|META592.85+14.31 (+2.47%) ▲|MMM168.75-1.49 (-0.88%) ▼|MO69.56-0.01 (-0.01%) ▼|MRK151.64+1.78 (+1.19%) ▲|MS211.82+0.78 (+0.37%) ▲|MSFT496.82-4.20 (-0.84%) ▼|MU956.08+22.64 (+2.43%) ▲|NEE83.10+0.17 (+0.21%) ▲|NFLX82.73+1.92 (+2.38%) ▲|NKE38.24+0.12 (+0.31%) ▲|NOW136.72-6.18 (-4.32%) ▼|NVDA224.41+6.97 (+3.21%) ▲|ORCL145.75+4.43 (+3.13%) ▲|PEP140.52+0.73 (+0.52%) ▲|PFE29.02+0.47 (+1.65%) ▲|PG147.64+1.43 (+0.98%) ▲|PLTR169.46-10.46 (-5.81%) ▼|PM187.94+0.79 (+0.42%) ▲|QCOM169.96+3.35 (+2.01%) ▲|RTX200.78-4.38 (-2.13%) ▼|SBUX106.72+0.57 (+0.54%) ▲|SCHW108.24-0.04 (-0.04%) ▼|SO88.31+0.22 (+0.25%) ▲|SPG210.20-1.67 (-0.79%) ▼|T25.95-0.05 (-0.19%) ▼|TMO608.54+8.04 (+1.34%) ▲|TMUS187.30+5.14 (+2.82%) ▲|TSLA357.01+0.92 (+0.26%) ▲|TXN254.80+1.46 (+0.58%) ▲|UBER76.45+1.21 (+1.61%) ▲|UNH399.66+3.36 (+0.85%) ▲|UNP289.73-0.89 (-0.31%) ▼|UPS103.01+0.35 (+0.34%) ▲|USB62.77+1.56 (+2.55%) ▲|V378.40+5.73 (+1.54%) ▲|VZ50.22-0.08 (-0.16%) ▼|WFC89.27+2.23 (+2.56%) ▲|WMT106.09+0.17 (+0.16%) ▲|XOM164.15-0.40 (-0.24%) ▼|
21.3 C
New York
Thursday, September 3, 2026

Tag: trial

newssourceFORcompanyinformationcontent1releasesmarket

82% of Adults with Type 2 Diabetes Not on Insulin Improve Blood Glucose Levels with Continuous Glucose Monitoring

New Study Highlights Potential of CGM to Help Patients Improve Diabetes Management in Primary Care SettingsNEW ORLEANS, June 6, 2026 /PRNewswire/ -- A new...

Breakthrough Studies Demonstrate Effectiveness of the First Triple-Hormone Therapy for Type 2 Diabetes and Obesity

Findings highlight use of once-weekly injection to expand potential options for weight reduction, A1C control, knee osteoarthritis, and obstructive sleep apneaNEW ORLEANS, June 6,...

Lilly’s triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity...

In TRIUMPH-1, participants on retatrutide 12 mg lost an average of 70.3 lbs (28.3%) over 80 weeks, with 65.3% achieving a BMI below 30,...

Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions

Post hoc analyses explored the impact of semaglutide across an array of conditions including obstructive sleep apnea (OSA), asthma-related adverse outcomes, liver health, cardiometabolic...

Her Bodhi Claims Evaluated: What Research Reveals About This Primal Queen Alternative, Weight Loss Support and Consumer Reviews

An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback. 
An independent, research-informed evaluation of the Her Bodhi botanical formula — examining its ingredient benefits, weight loss positioning, menopause wellness support, disclosed side effects, and publicly available consumer feedback.

People with type 2 diabetes who were increased to semaglutide 2 mg were as likely to achieve an HbA1c less than 7% and more...

Adults with type 2 diabetes on semaglutide 1 mg whose dose was increased to 2 mg were as likely to reach an HbA1c level...

Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes

New research supports monthly dosing as a next‑generation opportunity to improve weight lossNEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential...

Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978 

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind’s Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with...

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing...

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes 
• Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients treated with icovamenib, with no evidence of immune activation, and inflammatory markers stable or reduced
• Additionally, the Company expanded its Phase I BMF-650 study to evaluate a rapid one-step titration and enhanced weight loss potential with its oral GLP-1 receptor agonist

Bio Preventive Medicine and Precision Diabetes Announce ADA Late-Breaking Presentation Highlighting DNlite™ in Landmark CREDENCE Trial

New analysis supports DNlite™ for earlier renal risk stratification in patients with type 2 diabetes and chronic kidney diseaseZHUBEI CITY, Taiwan and RALEIGH, N.C.,...

Novo Nordisk’s investigational zenagamtide shows significant A1C reductions with up to 14.6% weight loss in adults with type 2 diabetes–presented at ADA 2026

A phase 2 study of investigational once-weekly subcutaneous zenagamtide showed statistically significant reductions in blood sugar in adults with type 2 diabetes compared to...

First Dual GLP-1/GIP Receptor Agonist Developed for Type 1 Diabetes Shows Promising Benefits in Blood Glucose Control

Phase 2 Study Results Highlight Use of Once-Daily Injection for Weight Loss and Reduction in Insulin UseNEW ORLEANS, June 5, 2026 /PRNewswire/ -- A...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTrial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers